# OnCo record mirvetuximab-soravtansine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mirvetuximab-soravtansine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mirvetuximab-soravtansine" ;
  schema:name "Mirvetuximab soravtansine"@en ;
  schema:description "Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha."@en ;
  schema:url <https://onco.cc/drugs/mirvetuximab-soravtansine/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mirvetuximab_soravtansine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q115285803> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mirvetuximab%20soravtansine> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Elahere" ;
  onco:approval "US 2022: FRα-high platinum-resistant ovarian cancer (full approval 2024)", "EU 2024: FRα+ platinum-resistant ovarian; 14 Nov 2024" ;
  onco:acceleratedApproval "US 2022-11-14: Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test" ;
  onco:acceleratedApprovalConfirmed "US 2024-03-22: Adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test" ;
  onco:related <https://onco.cc/biomarkers/folr1-expression/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/folr1/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:terms <https://onco.cc/terms/sulfo-spdb/>, <https://onco.cc/terms/ocular-toxicity/> ;
  onco:trials <https://onco.cc/trials/nct06682988/>, <https://onco.cc/trials/nct06365853/>, <https://onco.cc/trials/nct05456685/>, <https://onco.cc/trials/nct06890338/>, <https://onco.cc/trials/nct06390995/>, <https://onco.cc/trials/nct07059845/>, <https://onco.cc/trials/nct04274426/> .